Autres langues BioRestorative Therapies, Inc.

Actions

BRTX

US0906556065

Temps Différé Nasdaq Autres places de cotation 20:03:04 17/05/2024			Varia. 5j.	Varia. 1 janv.
1,35 ^USD	-2,17 %		-1,46 %	-22,41 %

15/05	BioRestorative annonce la signature d'un accord d'approvisionnement exclusif de cinq ans avec Cartessa Aesthetics, LLC	CI
08/05	BioRestorative Therapies, Inc. renforce son programme métabolique préclinique avec un nouveau produit biologique à base d'exosomes ciblant l'obésité	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BioRestorative Announces Signing a Five-Year Exclusive Supply Agreement with Cartessa Aesthetics, LLC	15/05
BioRestorative Therapies Provides First Quarter 2024 Business Update	14/05
BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity	08/05
BioRestorative Therapies, Inc. Enhances Preclinical Metabolic Program with A Novel Exosome-Based Biologic Targeting Obesity	08/05
BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024	30/04
BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology	30/04
BioRestorative Therapies, Inc. Announces Transformative Commercial Agreement with Cartessa Aesthetics, LLC	30/04
BioRestorative Therapies Shares Rise 17% After FDA Clears Phase 2 Study Protocol Amendment	16/04
BioRestorative Therapies Says US FDA Clears Amended Protocol for Phase 2 Cell Therapy Trial	16/04
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment	16/04
BioRestorative Therapies, Inc. Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment	16/04
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease	08/04
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease	08/04
BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants	03/04
BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K	01/04
BioRestorative Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
BioRestorative Therapies to Participate in the 36th Annual ROTH Conference	11/03
BioRestorative Therapies Presents Promising Data At Orthopaedic Research Society 2024 Annual Meeting	14/02
Top Midday Decliners	06/02
BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market	06/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues BioRestorative Therapies, Inc.

Actions

BRTX

US0906556065

Autres langues

Filtres